Obesity and preclinical changes of cardiac geometry and function

Korean Circulation Journal

Volumn 40, Issue 2, 2010, Pages 55-61

  Sung, Joong Kyung ^a   Kim, Jang Young ^a,b  

^a Wonju Severance Christian Hospital   (South Korea)

^b Yonsei University Wonju   (South Korea)

Author keywords

Diastole; Left ventricular dysfunction; Left ventricular hypertrophy; Obesity

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADIPOCYTOKINE; ADIPONECTIN; ANGIOTENSINOGEN; C REACTIVE PROTEIN; CATECHOLAMINE; CD36 ANTIGEN; FATTY ACID; FATTY ACID TRANSPORTER; FATTY ACID TRANSPORTER PROTEIN 1; GELATINASE A; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUROHORMONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; RIMONABANT; SIBUTRAMINE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TETRAHYDROLIPSTATIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOSE TISSUE; APOPTOSIS; BLOOD VOLUME; BODY MASS; COLLAGEN SYNTHESIS; DIET; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ECHOCARDIOGRAPHY; EPICARDIAL ADIPOSE TISSUE; EXTRACELLULAR MATRIX; FATTY ACID OXIDATION; FIBROSIS; GLUCOSE METABOLISM; HEART ATRIUM ENLARGEMENT; HEART ATRIUM FIBRILLATION; HEART FUNCTION; HEART LEFT ATRIUM; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART MUSCLE CELL; HEART MUSCLE METABOLISM; HEART MUSCLE OXYGEN CONSUMPTION; HEART OUTPUT; HEART SIZE; HEART VENTRICLE OVERLOAD; HEART VENTRICLE REMODELING; HEMODYNAMICS; HUMAN; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOXEMIA; INSULIN RESISTANCE; OBESITY; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SLEEP APNEA SYNDROME; THORAX PRESSURE; WEIGHT REDUCTION;

EID: 77949371062     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2010.40.2.55     Document Type: Review

References (71)

1. Park HS, Park CY, Oh SW, Yoo HJ. Prevalence of obesity and metabolic syndrome in Korean adults. Obes Rev 2008; 9; 104-7.
2. Kim HM, Park J, Kim HS, Kim DH, Park SH. Obesity and cardiovascular risk factor in Korean children and adolescents aged 10-18 years from the Korean National Health and Nutrition Examination Survey, 1998 and 2001. Am J Epidemiol 2006; 164: 787-93.
3. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67: 968-77.
4. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347: 305-13.
5. Barouch LA, Berkowitz DE, Harrison RW, O'Donnell CP, Hare JM. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 2003; 108: 754-9.
6. Korvald C, Elvenes OP, Myrmel T. Myocardial substrate metabolism influence left ventricular energetic in vivo. Am J Physiol Heart Circ Physiol 2000; 278: H1345-51.
7. Ouwens DM, Boer C, Fodor M, et al. Cardiac dysfunction induced by high -fat diet is associated with altered myocardial insulin signaling in rats. Diabetologia 2005; 48: 1229-37.
8. Avelar E, Cloward TV, Walker JM, et al. Left ventricular hypertrophy in severe obesity: interaction among blood pressure, nocturnal hypoxemia, body mass. Hypertension 2007; 49: 34-9.
9. Wong CY, O'Moore-Sullivan T, Leano R, Byrne N, Beller E, Marwick TH. Alterations of the left ventricular myocardial characteristics associated with obesity. Circulation 2004; 110: 3081-7.
10. Iacobellis G, Ribaudo MC, Zappaterreno A, Iannucci CV, Di Mario U, Leonetti F. Adapted changes in left ventricular struc ture and function in severe uncomplicated obesity. Obes Res 2004; 12: 1616-21.
11. Peterson LR, Waggoner AD, Schechtman KB, et al. Alterations in left ventricular structure and function in young healthy obese women: assessment by echocardiography and tissue Doppler imaging. J Am Coll Cardiol 2004; 43: 1399-404.
12. Sundstrom J, Lind L, Valind S, et al. Myocardial insulin-mediated glucose uptake and left ventricular geometry. Blood Press 2001; 10: 27-32.
13. Lauer MS, Anderson KM, Levy D. Separate and joint influence of obesity and mild hypertension on left ventricular mass and geometry: the Framingham Heart Study. J Am Coll Cardiol 1992; 19: 130-4.
14. Gottdiener JS, Reda DJ, Materson BJ, et al. Importance of obesity, race and age to the cardiac structure and functional effect of hypertension. J Am Coll Cardiol 1994; 24: 1492-8.
15. Fox E, Taylor H, Andrew M, et al. Body mass index and blood pressure influence on left ventricular mass and geometry in African Americans: the Atherosclerotic Risk In Communities (ARIC) Study Hypertension 2004; 44: 55-60.
16. Iacobellis G, Leonetti F. Epicardial adipose tissue and insulin resistance in obese subjects. J Clin Endocardial Metab 2005; 90: 6300-2.
17. Iacobellis G, Ribaudo MC, Zappaterreno A, Iannucci CV, Leonetti F. Relation between epicardial adipose tissue and left ventricular mass. Am J Cardiol 2004; 94: 1084-7.
18. Corradi D, Maestri R, Callegari S, et al. The ventricular epicardial fat is related to the myocardial mass in normal, ischemic and hypertrophic hearts. Cardiovasc Pathol 2004; 13: 313-6.
19. Malavazos AE, Ermetici F, Coman C, Corsi MM, Morricone L, Ambrosi B. Influence of epicardial adipose tissue and adipocytokine levels on cardiac abnormalities in visceral obesity. Int J Cardiol 2007; 121: 132-4.
20. Ayer JG, Almafragy HS, Patel AA, Hellyer RL, Celermajer DS. Body mass index is an independent determinant of left atrial size. Heart Lung Circ 2008; 17: 19-24.
21. Messerli FH, Ventura HO, Reisin E, et al. Borderline hypertension and obesity: two prehypertensive states with elevated cardiac output. Circulation 1982; 66: 55-60.
22. Pritchett AM, Mahoney DW, Jacobsen SJ, Rodeheffer RJ, Karon BL, Redfield MM. Diastolic dysfunction and left atrial volume: a population-based study. J Am Coll Cardiol 2005; 45: 87-92.
23. Wang TJ, Parise H, Levy D, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004; 292: 2471-7.
24. Tsang TS, Barnes ME, Miyasaka Y, et al. Obesity as a risk factor for the pregression of paroxysmal to permanent atrial fibrillation: a longitudinal cohort study of 21 years. Eur Heart J 2008; 29: 2227-33.
25. Messerli FH, Ventura HO, Reisin E, et al. Borderline hypertension and obesity: two prehypertensive states with elevated cardiac output. Circulation 1982; 66: 55-60.
26. Aurigemma GP, Silver KH, Priest MA, Gaasch WH. Geometric changes allow normal ejection fraction despite depressed myocardial myocardial shortening in hypertensive left ventricular hypertrophy. J Am Coll Cardiol 1995; 26: 195-202.
27. Garavaglia GE, Messerli FH, Nunez BD, Schmieder RE, Grossman E. Myocardial contractility and left ventricular function in obese patients with essential hypertension. Am J Cardiol 1988; 62; 594-7.
28. Aasum E, Hafstad AD, Severson DL, Larsen TS. Age-dependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from db/db mice. Diabetes 2003; 52: 434-41.
29. Peterson LR, Herrero P, Schechtman KB, et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 2004; 109; 2191-6.
30. Pascual M, Pascual DA, Soria F, et al. Effect of isolated obesity on systolic and diastolic left ventricular function. Heart 2003; 89: 1152-6.
31. Berkalp B, Cesur V, Corapcioglu D, Erol C, Baskal N. Obesity and left ventricular diastolic dysfunction. Int J Cardiol 1995; 52: 23-6.
32. Morricone L, Malavazos AE, Coman C, Donati C, Hassen T, Caviezel F. Echocardiography abnormalities in normotensive obese patients: relationship with visceral fat. Obes Res 2002; 10: 489-98.
33. Chakko S, Mayor M, Allison MD, Kessler KM, Materson BJ, Myerburg RJ. Abnormal left ventricular diastolic filling in eccentric left ventricular hypertrophy of obesity. Am J Cardiol 1991; 68: 95-8.
34. Christoffersen C, Bollano E, Lindegaard ML, et al. Cardiac lipid accumulation associated with diastolic dysfunction in obese mice. Endocrinology 2003; 144: 3483-90.
35. Kozakova M, Muscelli E, Flyvbjerg A, et al. Adiponectin and left ventricular structure and function in healthy adults. J Clin Endocrinol Metab 2008; 93: 2811-8.
36. Mizushige K, Yao L, Noma T, et al. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 2000; 101: 899-907.
37. Messerli FH, Christie B, DeCarvalho JGR, et al. Obesity and essential hypertension: hemodynamics, intravascular volume, sodium excretion, and plasma renin activity. Arch Intern Med 1981; 141: 81-5.
38. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999; 282: 1523-9.
39. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000; 342: 1378-84.
40. Quan SF, Gersh BJ. Cardiovascular consequences of sleep-disordered breathing: past, present and future: report of a workshop from the National Center on Sleep Disorders Research and the National Heart, Lung, Blood Institute. Circulation 2004; 109: 951-7.
41. Cloward TV, Walker JM, Farney RJ, Anderson JL. Left ventricular hypertrophy is a common echocardiography abnormality in severe obstructive sleep apnea and reverses with nasal continuous positive airway pressure. Chest 2003; 124: 594-601.
42. Buchanan J, Mazumder PK, Hu P, et al. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 2005; 146: 5341-9.
43. Mazumder PK, O'Neill BT, Roberts MW, et al. Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes 2004; 53: 2366-74.
44. Coort SL, Hasselbaink DM, Koonen DP, et al. Enhanced sarcolemmal FAT/CD 36 content and triacylglycerol storage in cardiac myocytes from obese zucker rats. Diabetes 2004; 53: 1655-63.
45. Semeniuk LM, Kryski AJ, Severson DL. Echocardiography assessment of cardiac function in diabetic db/db and transgenic db/db-hGLUT4 mice. Am J Physiol Heart Circ Physiol 2002; 283: H976-82.
46. Boudina S, Sena S, Theobald H, et al. Mitochondrial energetics in the heart in obesity related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes 2007; 56: 2457-66.
47. Unger RH. Lipotoxic disease. Annu Rev Med 2002; 53: 319-36.
48. Zhou YT, Grayburn P, Karim A, et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A 2000; 97: 1784-9.
49. Sidell RJ, Cole MA, Draper NJ, Desrois M, Buckingham RE, Clarke K. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker fatty rat heart. Diabetes 2002; 51: 1110-7.
50. Ruano M, Silvestre V, Castro R, et al. Morbid obesity, hypertensive disease and the rennin-angiotensin-aldosterone axis. Obes Surg 2005; 15: 670-6.
51. Hainault I, Nebout G, Turban S, Ardouin B, Ferre P, Quiqnard-Boulange A. Adipose tissue-specific increase in angiotensinogen expression and secretion in the obese (fa/fa) Zucker rat. Am J Physiol Endocrinol Metab 2002; 282: E59-66.
52. Davy KP, Hall JE. Obesity and hypertension: two epidemics or one? Am J Physiol Regul Integr Comp Physiol 2004; 286; R803-13.
53. Miner EC, Miller WL. A look between the cardiomyocytes: the extracellular matrix in heart failure. Mayo Clin Proc 2006; 81-71-6.
54. Quilliot D, Alla F, Bohme P, et al. Myocardial collagen turnover in normotensive obese patients: relation to insulin resistance. Int J Obes 2005; 29: 1321-8.
55. Carroll JF, Tyagi SC. Extracellular matrix remodeling in the heart of the homocysteinemic obese rabbit. Am J Hypertens 2005; 18: 692-8.
56. Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995; 269: 543-6.
57. Madani S, De Girolamo S, Munoz DM, Li RK, Sweeney G. Direct effects of leptin on size and extracellular matrix components of human pediatric ventricular myocytes. Cardiovasc Res 2006; 69: 716-25.
58. Park S, Cho YR, Kim HJ, et al. Unraveling the temporal pattern of diet-induced insulin resistance in individual organs and cardiac dysfunction in C57BL/6 mice. Diabetes 2005; 54: 3530-40.
59. Purdham D, Zou MX, Rajapurohitam V, Karmazyn M. Rat heart is a site of leptin production and action. Am J Physiol Heart Circ Physiol 2004; 287: H2877-84.
60. Kumada M, Kihara S, Ouchi N, et al. Adiponectin specifically increased TIMP-1 through interleukin-10 expression in human macrophages. Circulation 2004; 109: 2046-9.
61. Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med 1997; 336: 1131-41.
62. Communal C, Sumandea M, de Tombe P, Narula J, Solaro RJ, Hajjar RJ. Functional consequences of caspase activation in cardiac myocytes. Proc Natl Acad Sci U S A 2002; 99: 6252-6.
63. Cigola E, Kajstura J, Li B, Meggs LG, Anversa P. Angiotensin II activates programmed myocyte cell death in vitro. Exp Cell Res 1997; 231: 363-71.
64. Communal C, Singh K, Sawyer DB, Colucci WS. Opposing effects of beta 1- and beta2- adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis-toxin sensitive G protein. Circulation 1999; 100: 2210-2.
65. Relling DP, Esberg LB, Fang CX, et al. High-fat diet-induced juvenile obesity leads to cardiomyocyte dysfunction and upregulation of Foxo3a transcription factor independent of lipotoxicity and apoptosis. J Hypertens 2006; 24: 549-61.
66. Alpert MA, Lambert CR, Panayiotou H, et al. Relation of duration of morbid obesity to left ventricular mass, systolic function, and diastolic filling, and effect of weight loss. Am J Cardiol 1995; 76: 1194-7.
67. Klein S, Fontana L, Young VL, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 2004; 350: 2549-57.
68. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care 2004; 27: 155-61.
69. Wadden TA, Berkowitz RI, Womble LG, et al. Randomised trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005; 353: 2111-20.
70. Curioni C, Andre C. Rimonabant for overweight or obesity. Cochrane Database Syst Rev 2006; 4: CD006162.
71. Padwal RS, Majumdar SR. Drug treatments for obesity: oristat, sibutramine, and rimonabant. Lancet 2007; 369: 71-7.